title: 18F-FDG PET/CT in the Staging and Management of Breast Cancer: Value in Disease Outcome and Planning Therapy.
abstract: In hormone receptor-positive locally advanced breast cancer, endocrine therapy becomes an integral part of the therapeutic strategy. There are now significant numbers of available hormonal directed compounds, including selective aromatase and mTOR inhibitors, which allow an important therapeutic advance in these patients. Sequential F-FDG PET/CT studies provided essential information regarding response to different treatments, including targeted therapies, and adverse therapeutic effects that helped to better define the right moment to implement each therapeutic approach.
authors.affiliation: From the *Unidad PET/TC, CETIR-ERESA, C/J Anselm Clave, Esplugues, Barcelona; and †Servicio Oncología, Hospital Sant Pau i Santa Tecla, Tarragona, Spain.
authors.forename: J R
authors.initials: JR
authors.lastname: Garcia
authors.forename: Cristina
authors.initials: C
authors.lastname: Pérez
authors.forename: Pere
authors.initials: P
authors.lastname: Bassa
authors.forename: Laia
authors.initials: L
authors.lastname: Capdevila
authors.forename: Francisco
authors.initials: F
authors.lastname: Ramos
authors.forename: Vicens
authors.initials: V
authors.lastname: Valenti
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D047072:Aromatase Inhibitors / Q000627:therapeutic use; D001365:Axilla; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000000981:diagnostic imaging* / Q000556:secondary; D001943:Breast Neoplasms / Q000000981:diagnostic imaging* / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D003520:Cyclophosphamide / Q000627:therapeutic use; D004164:Diphosphonates / Q000627:therapeutic use; D000077143:Docetaxel; D015251:Epirubicin / Q000627:therapeutic use; D005260:Female; D019788:Fluorodeoxyglucose F18; D005472:Fluorouracil / Q000627:therapeutic use; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D000077289:Letrozole; D008197:Lymph Node Excision; D008198:Lymph Nodes / Q000000981:diagnostic imaging*; D008408:Mastectomy; D064847:Multimodal Imaging; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D009570:Nitriles / Q000627:therapeutic use; D000072078:Positron Emission Tomography Computed Tomography; D019275:Radiopharmaceuticals; D011878:Radiotherapy; D012272:Ribs / Q000000981:diagnostic imaging*; D043823:Taxoids / Q000008:administration & dosage; D014230:Triazoles / Q000627:therapeutic use; D000077211:Zoledronic Acid
chemical_list: D047072:Aromatase Inhibitors; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D009570:Nitriles; D019275:Radiopharmaceuticals; D043823:Taxoids; D014230:Triazoles; D019788:Fluorodeoxyglucose F18; D000077143:Docetaxel; D007987:Gonadotropin-Releasing Hormone; D015251:Epirubicin; D000077211:Zoledronic Acid; D000077289:Letrozole; D003520:Cyclophosphamide; D005472:Fluorouracil